Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lymphoma drug safety under the microscope in 1,000-Patient study

NCT ID NCT04837222

Knowledge-focused Sponsor: Takeda Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 6 times

Summary

This study follows 1,000 people with CD30-positive lymphoma who are already receiving or about to receive brentuximab vedotin as part of their normal care. Researchers will track side effects and how the drug is used in everyday practice, without giving any new treatment. The goal is to better understand the drug's real-world safety and effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,000 people

The number who actually took part.

Started

Jun 2021

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with CD30-positive lymphoma, who have been prescribed brentuximab vedotin in clinical practice will be observed prospectively.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Undergoing treatment with brentuximab vedotin (of less than 3 months from initial treatment with brentuximab vedotin) or to be received with brentuximab vedotin. 2. CD30-positive lymphoma by INV (any CD30 expression) Exclusion Criteria: 1\. Who currently participates in or with plan to participate in any interventional clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CD30-positive lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anaplastic large cell lymphoma lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphoma

Contacts and locations

Locations

  • Affiliated Hodpital of Nantong University

    Nantong, Jiangsu, 226001, China

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, 230001, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200032, China

  • Hematology Hospital of Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, 300020, China

  • HenanProvincial CancerHospital

    Zhengzhou, Henan, 450003, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, 210029, China

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, 100010, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, 100044, China

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, 518035, China

  • Peking University Third Hospita

    Beijing, Beijing Municipality, 100191, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, 250012, China

  • Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, 200025, China

  • ShandongProvincial CancerHospital

    Jinan, Shandong, 250117, China

  • ShanxiProvincial CancerHospital

    Taiyuan, Shanxi, 030013, China

  • The Affiliated People's Hospital of Ningbo University

    Ningbo, Zhejiang, 315040, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510280, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, 471003, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, 330006, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, 215006, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, 361003, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, 050011, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310052, China

  • The Second Hospital of Dalian Medical University

    Dalian, Liaoning, 116027, China

  • The first hospital of Jilin University

    Changchun, Jilin, 130021, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, 300060, China

  • Tianjin People's Hospital

    Tianjin, Tianjin Municipality, 300121, China

  • Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, 430022, China

  • Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, 430023, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, 610041, China

  • Yunnan First People's Hospital

    Kunming, Yunnan, 650032, China

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, 210009, China

  • ZhuJiang Hosptital of Southern Medical University

    Guangzhou, Guangdong, 510280, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.